1.World Health Organization, International Agency for Research on Cancer: IARC monographs on the evaluation of carcinogenic risks to humans: schistosomes, liver lukes, and Helicobacter pylori. vol 61 Lyon: IARC, 1994.
2.Chen XZ, Schöttker B, Castro FA, Chen H, Zhang Y, Holleczek B, Brenner H: Association of helicobacter pylori infection and chronic atrophic gastritis with risk of colonic, pancreatic and gastric cancer: A ten-year follow-up of the ESTHER cohort study. Oncotarget 2016, 7(13):17182–17193.
3.Yoshida T, Kato J, Inoue I, Yoshimura N, Deguchi H, Mukoubayashi C, Oka M, Watanabe M, Enomoto S, Niwa T et al: Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer. Int J Cancer 2014, 134(6):1445–1457.
4.Song H, Held M, Sandin S, Rautelin H, Eliasson M, Soderberg S, Hallmans G, Engstrand L, Nyren O, Ye W: Increase in the Prevalence of Atrophic Gastritis Among Adults Age 35 to 44 Years Old in Northern Sweden Between 1990 and 2009. Clin Gastroenterol Hepatol 2015, 13(9):1592–1600 e1591.
5.Sugano K: Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis. Gastric Cancer 2018.
6.Pasechnikov V, Chukov S, Fedorov E, Kikuste I, Leja M: Gastric cancer: prevention, screening and early diagnosis. World journal of gastroenterology: WJG 2014, 20(38):13842–13862.
7.Chen XZ, Zhang WH, Hu JK: A difficulty in improving population survival outcome of gastric cancer in mainland China: low proportion of early diseases. Medical oncology (Northwood, London, England) 2014, 31(12):315.
8.Wang R, Chen XZ: High mortality from hepatic, gastric and esophageal cancers in mainland China: 40 years of experience and development. Clinics and research in hepatology and gastroenterology 2014, 38(6):751–756.
9.Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB: Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283(15):2008–2012.
10.Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6(7):e1000097.
11.Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. URL: http://wwwohrica/programs/clinical_epidemiology/oxfordhtm [Accessed Dec 29 2018].
12.Review Manager (RevMan) [Computer program]: Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
13.StataCorp LP: Stata/SE 12.0 for Windows. 4905 Lakeway Drive College Station, TX 77845, USA 2011. www.stata.com.
14.Hintze J: (2011). PASS 11. NCSS, LLC. Kaysville, Utah, USA. www.ncss.com.
15.Chen XZ, Wang R, Chen HN, Hu JK: Cytotoxin-associated gene A-negative strains of Helicobacter pylori as a potential risk factor of pancreatic cancer: A meta-analysis based on nested case-control studies. Pancreas 2015, 44(8):1340–1344.
16.Liu H, Chen YT, Wang R, Chen XZ: Helicobacter pylori infection, atrophic gastritis, and pancreatic cancer risk: A meta-analysis of prospective epidemiologic studies. Medicine 2017, 96(33):e7811.
17.Jiang HJ, Jiang JB: Relationship between common gastrointestinal diseases and Helicobacter pylori in Lhasa area between Han and Tibetan ethnics. Med J Chin PLA 1992, 17(5):386. In Chinese.
18.Wang XM: Differences in Helicobacter pylori infection in chronic gastritis and peptic ulcer among Han and Tibetan ethnics. Chin J Dig 1994, 14(6):322. In Chinese.
19.Yang DP, Luo ZL, He GG, Yuan YY, Mou WL, Zhang BT, Sun LY, Liu DJ: Epidemiological survey on Helicobacter pylori infection among natural population at Shigatse city in Tibet. Chin J Epidemiol 1997, 18(2):125.
20.Wang PX, Zhang XR, Yin YF: Ten-year retrospective analysis on the association of Helicobacter pylori with precancerous conditions and gastric cancer among Hui, Tibetan, and Han races. World Chin J Digestol 2000, 8(3):368.
21.Zhao GB: Characteristics of gastric and duodenal diseases and Helicobacter pylori infection of Sichuan and Tibetan ethnics. Chin J Dig Endosc 2000, 17(1):51–52. In Chinese.
22.Dan Z, Liu XB: Epidemiological investigation of Helicobacter pylori in 56 students from different regions. Tibet Med J 2001, 22(4):23–24. In Chinese.
23.Dan Z, Wang J, Za X, Liu XB, Ba S, Ciren YJ: Examination of serum Helicobacter pylori antibody at Lhasa region. World Chin J Digestol 2001, 9(7):762.
24.Cao P, Lu QM, Zhang YL, Zhang LP, Jiang R, Li SL, Chen X, Ma HM, Shi LQ, Ma QR et al: Epidemiologic study of Helicobacter pylori infection in Tianzhu and Lanzhou areas. Chin J Gastroenterol Hepatol 2005, 14(2):175–177.
25.Bao JL: Prevalence of Helicobacter pylori infection and association between Tibetan and Han races at Lhoka prefecture in Tibet. Tibet Sci Tech 2012, 19(7):58.
26.Wang H, Yang JM: Survey on Helicobacter pylori infection among population at Yushu prefecture. Lab Med Clin 2013, 10(6):731–732.
27.Wang R, Zhang MG, Chen XZ, Wu H: Risk population of Helicobacter pylori infection among Han and Tibetan ethnicities in western China: a cross-sectional, longitudinal epidemiological study. Lancet 2016, 388(Suppl 1):S17.
28.Nagy P, Johansson S, Molloy-Bland M: Systematic review of time trends in the prevalence of Helicobacter pylori infection in China and the USA. Gut pathogens 2016, 8:8.
29.McDonald AM, Sarfati D, Baker MG, Blakely T: Trends in Helicobacter pylori infection among Maori, Pacific, and European Birth cohorts in New Zealand. Helicobacter 2015, 20(2):139–145.
30.Lim SH, Kwon JW, Kim N, Kim GH, Kang JM, Park MJ, Yim JY, Kim HU, Baik GH, Seo GS et al: Prevalence and risk factors of Helicobacter pylori infection in Korea: nationwide multicenter study over 13 years. BMC gastroenterology 2013, 13:104.
31.Ueda J, Gosho M, Inui Y, Matsuda T, Sakakibara M, Mabe K, Nakajima S, Shimoyama T, Yasuda M, Kawai T et al: Prevalence of Helicobacter pylori infection by birth year and geographic area in Japan. Helicobacter 2014, 19(2):105–110.
32.Binh TT, Tuan VP, Dung HDQ, Tung PH, Tri TD, Thuan NPM, Tam LQ, Nam BC, Giang DA, Hoan PQ et al: Molecular Epidemiology of Helicobacter pylori Infection in a Minor Ethnic Group of Vietnam: A Multiethnic, Population-Based Study. International journal of molecular sciences 2018, 19(3).
33.Subsomwong P, Miftahussurur M, Vilaichone RK, Ratanachu-Ek T, Suzuki R, Akada J, Uchida T, Mahachai V, Yamaoka Y: Helicobacter pylori virulence genes of minor ethnic groups in North Thailand. Gut pathogens 2017, 9:56.
34.Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P: Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ (Clinical research ed) 2014, 348:g3174.
35.Lee YC, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS, Graham DY: Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. Gastroenterology 2016, 150(5):1113–1124 e1115.
36.Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY et al: Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. Jama 2004, 291(2):187–194.
37.Choi IJ, Kook MC, Kim YI, Cho SJ, Lee JY, Kim CG, Park B, Nam BH: Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer. The New England journal of medicine 2018, 378(12):1085–1095.
38.Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, Terao S, Amagai K, Hayashi S, Asaka M: Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet (London, England) 2008, 372(9636):392–397.
39.Yoon SB, Park JM, Lim CH, Cho YK, Choi MG: Effect of Helicobacter pylori eradication on metachronous gastric cancer after endoscopic resection of gastric tumors: a meta-analysis. Helicobacter 2014, 19(4):243–248.
40.Weck MN, Gao L, Brenner H: Helicobacter pylori infection and chronic atrophic gastritis: associations according to severity of disease. Epidemiology (Cambridge, Mass) 2009, 20(4):569–574.
41.Vannarath S, Vilaichone RK, Rasachak B, Mairiang P, Yamaoka Y, Shiota S, Binh TT, Mahachai V: Virulence genes of Helicobacter pylori in gastritis, peptic ulcer and gastric cancer in Laos. Asian Pacific journal of cancer prevention: APJCP 2014, 15(20):9027–9031.
42.Inagaki T, Nishiumi S, Ito Y, Yamakawa A, Yamazaki Y, Yoshida M, Azuma T: Associations Between CagA, VacA, and the Clinical Outcomes of Helicobacter Pylori Infections in Okinawa, Japan. The Kobe journal of medical sciences 2017, 63(2):E58-E67.
43.Marie MA: Relationship between Helicobacter pylori virulence genes and clinical outcomes in Saudi patients. Journal of Korean medical science 2012, 27(2):190–193.
44.Paniagua GL, Monroy E, Rodriguez R, Arroniz S, Rodriguez C, Cortes JL, Camacho A, Negrete E, Vaca S: Frequency of vacA, cagA and babA2 virulence markers in Helicobacter pylori strains isolated from Mexican patients with chronic gastritis. Annals of clinical microbiology and antimicrobials 2009, 8:14.
45.Mattar R, dos Santos AF, Eisig JN, Rodrigues TN, Silva FM, Lupinacci RM, Iriya K, Carrilho FJ: No correlation of babA2 with vacA and cagA genotypes of Helicobacter pylori and grading of gastritis from peptic ulcer disease patients in Brazil. Helicobacter 2005, 10(6):601–608.